Related references
Note: Only part of the references are listed.Diagnosis and treatment of chronic synovitis in patients with haemophilia: consensus statements from the Italian Association of Haemophilia Centres
Matteo Nicola Dario Di Minno et al.
BRITISH JOURNAL OF HAEMATOLOGY (2022)
Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors
Giovanni Di Minno et al.
HAEMOPHILIA (2022)
Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A
Robert Klamroth et al.
HUMAN GENE THERAPY (2022)
Thrombin generation for monitoring hemostatic therapy in hemophilia A: A narrative review
Marieke J. A. Verhagen et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2022)
Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study
Toshko Lissitchkov et al.
BLOOD ADVANCES (2022)
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A
M. C. Ozelo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B
Pratima Chowdary et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Thrombin generation measured on ST Genesia, a new platform in the coagulation routine lab: Assessment of analytical and between-subject variation
Soren Risom Kristensen et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2022)
The evolving landscape of gene therapy for congenital haemophilia: An unprecedented, problematic but promising opportunity for worldwide clinical studies
Gaia Spadarella et al.
BLOOD REVIEWS (2021)
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies
Michael U. Callaghan et al.
BLOOD (2021)
Outcome measures in Haemophilia: Beyond ABR (Annualized Bleeding Rate)
Marilyn J. Manco-Johnson et al.
HAEMOPHILIA (2021)
Current Clinical Applications of In Vivo Gene Therapy with AAVs
Jerry R. Mendell et al.
MOLECULAR THERAPY (2021)
A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells
Giang N. Nguyen et al.
NATURE BIOTECHNOLOGY (2021)
Enhanced Half-Life Recombinant Factor VIII Concentrates for Hemophilia A: Insights from Pivotal and Extension Studies
Matteo Nicola Dario Di Minno et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2021)
Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort
K. John Pasi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)
Gene Therapy for Inherited Bleeding Disorders
Valder R. Arruda et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2021)
Discussing investigational AAV gene therapy with hemophilia patients: A guide
Robert F. Sidonio Jr et al.
BLOOD REVIEWS (2021)
Post-authorization pharmacovigilance for hemophilia in Europe and the USA: Independence and transparency are keys
Flora Peyvandi et al.
BLOOD REVIEWS (2021)
Perspective-The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021
Alessandro Di Minno et al.
BLOOD REVIEWS (2021)
Hemophilia gene therapy: ushering in a new treatment paradigm?
Lindsey A. George
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2021)
Comparative analysis of the pivotal studies of extended half-life recombinant FVIII products for treatment of haemophilia A
Pier Mannuccio Mannucci et al.
HAEMOPHILIA (2021)
Evolution of haemophilia integrated care in the era of gene therapy: Treatment centre's readiness in United States and EU
Wolfgang Miesbach et al.
HAEMOPHILIA (2021)
Optimizing language for effective communication of gene therapy concepts with hemophilia patients: a qualitative study
Daniel P. Hart et al.
ORPHANET JOURNAL OF RARE DISEASES (2021)
Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A
K. John Pasi et al.
HAEMOPHILIA (2021)
AAV integration in human hepatocytes
Dhwanil A. Dalwadi et al.
MOLECULAR THERAPY (2021)
Monitoring cell-mediated immune responses in AAV gene therapy clinical trials using a validated IFN-γ ELISpot method
Kathryn S. Patton et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2021)
Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia
Paul E. Monahan et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Living with a hemophilia-free mind - The new ambition o hemophilia care?
Evelien Krumb et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2021)
Hemophilia Gene Therapy: Approaching the First Licensed Product
Paul Batty et al.
HEMASPHERE (2021)
Adeno-associated virus in the liver: natural history and consequences in tumour development
Tiziana La Bella et al.
GUT (2020)
Paradigm shift for the treatment of hereditary haemophilia: Towards precision medicine
Gaia Spadarells et al.
BLOOD REVIEWS (2020)
World Federation of Hemophilia Gene Therapy Registry
Barbara A. Konkle et al.
HAEMOPHILIA (2020)
Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis
Pratima Chowdary et al.
THROMBOSIS AND HAEMOSTASIS (2020)
The Patient Experience of Gene Therapy for Hemophilia: Qualitative Interviews with Trial Patients
Wolfgang Miesbach et al.
PATIENT PREFERENCE AND ADHERENCE (2020)
IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies
Christian Leborgne et al.
NATURE MEDICINE (2020)
Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia
Peter L. Turecek et al.
HAEMOPHILIA (2020)
Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B
Lindsey A. George et al.
MOLECULAR THERAPY (2020)
Treatment of Hemophilia - More Amazing Progress
Pier M. Mannucci
NEW ENGLAND JOURNAL OF MEDICINE (2020)
BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A
Barbara A. Konkle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A
K. John Pasi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Surviving in the Valley of Death: Opportunities and Challenges in Translating Academic Drug Discoveries
Marcus C. Parrish et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 59 (2019)
The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab
Manuel Carcao et al.
HAEMOPHILIA (2019)
Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
Manuel D. Carcao et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2019)
Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates
Michela Milani et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies?
Jane F. Barlow et al.
VALUE IN HEALTH (2019)
Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs
Anna Majowicz et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2019)
Emicizumab for the prevention of bleeds in hemophilia A
Johnny Mahlangu
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Clinical advances in gene therapy updates on clinical trials of gene therapy in haemophilia
Flora Peyvandi et al.
HAEMOPHILIA (2019)
The national blueprint for future factor VIII inhibitor clinical trials: NHLBI State of the Science (SOS) Workshop on factor VIII inhibitors
Margaret V. Ragni et al.
HAEMOPHILIA (2019)
Gene therapy for hemophilia: Progress to date and challenges moving forward
Kandace L. Gollomp et al.
TRANSFUSION AND APHERESIS SCIENCE (2019)
Clinical Considerations for Capsid Choice in the Development of Liver-Targeted AAV-Based Gene Transfer
Steven Pipe et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2019)
Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients
Rolf Ljung et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor
I. M. Rietveld et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2019)
Gene therapy for hemophilia
Amit C. Nathwani
Hematology-American Society of Hematology Education Program (2019)
Perspective on Adenoviruses: Epidemiology, Pathogenicity, and Gene Therapy
Brennetta J. Crenshaw et al.
BIOMEDICINES (2019)
Hemophilia trials in the twenty-first century: Defining patient important outcomes
Barbara A. Konkle et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2019)
Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein
J. Oldenburg et al.
HAEMOPHILIA (2018)
Hemophilia gene therapy is effective and safe
Michael Makris
BLOOD (2018)
Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project
A. Iorio et al.
HAEMOPHILIA (2018)
Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH
M. V. Ragni et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
Measuring success in hemophilia gene therapy using a factor level & outcomes yardstick
Nicoletta Machin et al.
EXPERT REVIEW OF HEMATOLOGY (2018)
The elevated prevalence of risk factors for chronic liver disease among ageing people with hemophilia and implications for treatment
Christian Qvigstad et al.
MEDICINE (2018)
Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration
Amine Meliani et al.
NATURE COMMUNICATIONS (2018)
A cross-sectional analysis of cardiovascular disease in the hemophilia population
Suman L. Sood et al.
BLOOD ADVANCES (2018)
Navigating Speed Bumps on the Innovation Highway in Hemophilia Therapeutics
Donna M. DiMichele
HEMASPHERE (2018)
Gene therapy for hemophilia: what does the future hold?
Bhavya S. Doshi et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2018)
The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B
J. Michael Soucie et al.
BLOOD ADVANCES (2018)
Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B
Wolfgang Miesbach et al.
BLOOD (2018)
Gene therapy in hemophilia A: a cost-effectiveness analysis
Nicoletta Machin et al.
BLOOD ADVANCES (2018)
Tailoring of medical treatment: hemostasis and thrombosis towards precision medicine
Giovanni Di Minno et al.
HAEMATOLOGICA (2017)
Impact of AAV Capsid-Specific T-Cell Responses on Design and Outcome of Clinical Gene Transfer Trials with Recombinant Adeno-Associated Viral Vectors: An Evolving Controversy
Hildegund C. J. Ertl et al.
HUMAN GENE THERAPY (2017)
Advances in Gene Therapy for Hemophilia
Amit C. Nathwani et al.
HUMAN GENE THERAPY (2017)
In Utero Transfer of Adeno-Associated Viral Vectors Produces Long-Term Factor IX Levels in a Cynomolgus Macaque Model
Citra N. Z. Mattar et al.
MOLECULAR THERAPY (2017)
Identification of liver-specific enhancer-promoter activity in the 3′ untranslated region of the wild-type AAV2 genome
Grant J. Logan et al.
NATURE GENETICS (2017)
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
L. A. George et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
AAV5-Factor VIII Gene Transfer in Severe Hemophilia A
Savita Rangarajan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Factor Villa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens
Takehisa Kitazawa et al.
THROMBOSIS AND HAEMOSTASIS (2017)
Tailoring of medical treatment: hemostasis and thrombosis towards precision medicine
Giovanni Di Minno et al.
HAEMATOLOGICA (2017)
Hemophilia gene therapy comes of age
Lindsey A. George
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2017)
Novel approaches to hemophilia therapy: successes and challenges
Valder R. Arruda et al.
BLOOD (2017)
Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine
Cody S. Lee et al.
GENES & DISEASES (2017)
Progress and challenges in viral vector manufacturing
Johannes C. M. van der Loo et al.
HUMAN MOLECULAR GENETICS (2016)
Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders
Giovanni Di Minno et al.
BLOOD REVIEWS (2016)
Thrombin Generation Assay and Its Application in the Clinical Laboratory
Armando Tripodi
CLINICAL CHEMISTRY (2016)
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals
Fabio Conti et al.
JOURNAL OF HEPATOLOGY (2016)
Gene therapy for immune tolerance induction in hemophilia with inhibitors
V. R. Arruda et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
Genotoxicity in Mice Following AAV Gene Delivery: A Safety Concern for Human Gene Therapy?
Randy J. Chandler et al.
MOLECULAR THERAPY (2016)
LIVER CANCER Effect of HCV clearance with direct-acting antiviral agents on HCC
Josep M. Llovet et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2016)
Assessment of Hemophilic Arthropathy by Ultrasound: Where Do We Stand?
Matteo Nicola Dario Di Minno et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2016)
Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice
Amy M. Lange et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2016)
Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models
Joshua I. Siner et al.
JCI INSIGHT (2016)
AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice
Julie M. Crudele et al.
BLOOD (2015)
Cardiovascular precision medicine: hope or hype?
Geoffrey S. Pitt
EUROPEAN HEART JOURNAL (2015)
Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy
Randy J. Chandler et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas
Jean-Charles Nault et al.
NATURE GENETICS (2015)
Factor VIII Is Synthesized in Human Endothelial Cells, Packaged in Weibel-Palade Bodies and Secreted Bound to ULVWF Strings
Nancy A. Turner et al.
PLOS ONE (2015)
Liver-directed lentiviral gene therapy in a dog model of hemophilia B
Alessio Cantore et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Phenotypic Heterogeneity of Hemostasis in Severe Hemophilia
Keiji Nogami et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2015)
Murine coagulation factor VIII is synthesized in endothelial cells
Lesley A. Everett et al.
BLOOD (2014)
Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS
S. Lalezari et al.
HAEMOPHILIA (2014)
Our Journey to Successful Gene Therapy for Hemophilia B
Amit C. Nathwani et al.
HUMAN GENE THERAPY (2014)
The Prevalence of Neutralizing Antibodies Against Adeno-Associated Virus Capsids Is Reduced in Young Japanese Individuals
Jun Mimuro et al.
JOURNAL OF MEDICAL VIROLOGY (2014)
Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII
T. Shahani et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Engineering adeno-associated viruses for clinical gene therapy
Melissa A. Kotterman et al.
NATURE REVIEWS GENETICS (2014)
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
A. C. Nathwani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Federico Mingozzi et al.
BLOOD (2013)
Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant
Jenny McIntosh et al.
BLOOD (2013)
Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A
Lily M. Du et al.
NATURE COMMUNICATIONS (2013)
Pre-existing Anti-Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy
Vedell Louis Jeune et al.
HUMAN GENE THERAPY METHODS (2013)
Humoral immune response to AAV
Roberto Calcedo et al.
FRONTIERS IN IMMUNOLOGY (2013)
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection
Valentina Svicher et al.
ANTIVIRAL RESEARCH (2012)
Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
Jerry S. Powell et al.
BLOOD (2012)
Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer
George Buchlis et al.
BLOOD (2012)
The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy
Jonathan D. Finn et al.
BLOOD (2012)
Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia
C. Li et al.
GENE THERAPY (2012)
Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates
Carmen Unzu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model
Takehisa Kitazawa et al.
NATURE MEDICINE (2012)
Adeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents
Roberto Calcedo et al.
CLINICAL AND VACCINE IMMUNOLOGY (2011)
Immune Responses to AAV in Clinical Trials
Federico Mingozzi et al.
CURRENT GENE THERAPY (2011)
Perinatal Gene Transfer to the Liver
Tristan R. McKay et al.
CURRENT PHARMACEUTICAL DESIGN (2011)
Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels
I. E. M. den Uijl et al.
HAEMOPHILIA (2011)
Clinical severity of haemophilia A: does the classification of the 1950s still stand?
I. E. M. Den Uijl et al.
HAEMOPHILIA (2011)
DLK1-DIO3 Genomic Imprinted MicroRNA Cluster at 14q32.2 Defines a Stemlike Subtype of Hepatocellular Carcinoma Associated with Poor Survival
John M. Luk et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Gene therapy for haemophilia: a long and winding road
K. A. High
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
A 10 Patient Case Report on the Impact of Plasmapheresis Upon Neutralizing Factors Against Adeno-associated Virus (AAV) Types 1, 2, 6, and 8
Virginie Monteilhet et al.
MOLECULAR THERAPY (2011)
Efficacy and Safety of Long-term Prophylaxis in Severe Hemophilia A Dogs Following Liver Gene Therapy Using AAV Vectors
Denise E. Sabatino et al.
MOLECULAR THERAPY (2011)
In vivo efficacy of platelet-delivered, high specific activity factor VIII variants
Teshell K. Greene et al.
BLOOD (2010)
Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy
Jonathan D. Finn et al.
BLOOD (2010)
Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches
Antonio Coppola et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors
Sylvie Boutin et al.
HUMAN GENE THERAPY (2010)
How we treat a hemophilia A patient with a factor VIII inhibitor
Christine L. Kempton et al.
BLOOD (2009)
Extrahepatic factor VIII production in transplant recipient of hemophilia donor liver
Charles L. Madeira et al.
BLOOD (2009)
AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells
Federico Mingozzi et al.
BLOOD (2009)
How I treat age-related morbidities in elderly persons with hemophilia
Pier M. Mannucci et al.
BLOOD (2009)
Hepatic Gene Transfer as a Means of Tolerance Induction to Transgene Products
Paul A. LoDuca et al.
CURRENT GENE THERAPY (2009)
Effect of Adeno-Associated Virus Serotype and Genomic Structure on Liver Transduction and Biodistribution in Mice of Both Genders
Astrid Paneda et al.
HUMAN GENE THERAPY (2009)
Evolution of recombinant factor VIII safety: KOGENATEA® and KogenateA® FS/Bayer
Jeanne M. Lusher et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2009)
X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua)
Paolo Simioni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The phenotypic heterogeneity of severe hemophilia
Giridhara Rao Jayandharan et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2008)
Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver
Federico Mingozzi et al.
BLOOD (2007)
Inhibitor development in haemophilia B: an orphan disease in need of attention
Donna DiMichele
BRITISH JOURNAL OF HAEMATOLOGY (2007)
AAV vector integration sites in mouse hepatocellular carcinoma
Anthony Donsante et al.
SCIENCE (2007)
Reconstruction of the hepatitis C virus epidemic in the US hemophilia population, 1940-1990
James J. Goedert et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2007)
Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B
Haiyan Jiang et al.
MOLECULAR THERAPY (2006)
Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies
Qizhen Shi et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Inadvertent germline transmission of AAV2 vector: Findings in a rabbit model correlate with those in a human clinical trial
Joerg Schuettrumpf et al.
MOLECULAR THERAPY (2006)
Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response
CS Manno et al.
NATURE MEDICINE (2006)
High levels of persistent expression of (A-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses
BP De et al.
MOLECULAR THERAPY (2006)
Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy
LL Wang et al.
BLOOD (2005)
Bioengineering of coagulation factor VIR for improved secretion
HZ Miao et al.
BLOOD (2004)
Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group
A Gringeri et al.
BLOOD (2003)
Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway
AM Davidoff et al.
BLOOD (2003)
AAV serotype 2 vectors preferentially integrate into active genes in mice
H Nakai et al.
NATURE GENETICS (2003)
Identification of a new imprinted gene, Rian, on mouse chromosome 12 by fluorescent differential display screening
I Hatada et al.
JOURNAL OF BIOCHEMISTRY (2001)
Medical progress - The hemophilias - From royal genes to gene therapy
PM Mannucci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Definitions in hemophilia - Recommendation of the Scientific Subcommittee on factor VIII and factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
GC White et al.
THROMBOSIS AND HAEMOSTASIS (2001)
Share Paper
